Influenza vaccination is associated with reduced severity of community-acquired pneumonia

European Respiratory Journal

Volumn 38, Issue 1, 2011, Pages 147-153

  Tessmer, A ^a   Welte, T ^b   Schmidt Ott, R ^c   Eberle, S ^c   Barten, G ^b   Suttorp, N ^a   Schaberg, T ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GLAXOSMITHKLINE   (Germany)

^d Diakonie Hospital Rotenburg Wümme   (Germany)

Author keywords

Community acquired pneumonia; Influenza; Mortality; Vaccination

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; PROCALCITONIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CURB SCORE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GERMANY; HUMAN; INFLUENZA VACCINATION; MALE; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL TIME;

AGED; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GERMANY; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PNEUMONIA; SEASONS; TREATMENT OUTCOME; VACCINATION;

EID: 79960176449     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00133510     Document Type: Article

References (31)

1. Louria DB, Blumenfeld HL, Ellis JT, et al. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959; 38: 213-265.
2. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198: 962-970.
3. Herold S, Steinmueller M, von Wulffen W, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 2008; 205: 3065-3077.
4. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009; 119: 1910-1920.
5. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558-564. (Pubitemid 351655219)
6. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008; 205: 323-329. (Pubitemid 351281598)
7. Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; 2: CD001269.
8. Voordouw BC, Sturkenboom MC, Dieleman JP, et al. Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. Arch Intern Med 2006; 166: 1980-1985. (Pubitemid 44537178)
9. Wang CS, Wang ST, Lai CT, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine 2007; 25: 1196-1203.
10. Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357: 1373-1381. (Pubitemid 47535592)
11. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947-592.
12. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965. (Pubitemid 39490781)
13. Spaude KA, Abrutyn E, Kirchner C, et al. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007; 167: 53-59. (Pubitemid 46072407)
14. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382. (Pubitemid 36560938)
15. Hoffken G, Lorenz J, Kern W, et al. [S3-guideline on ambulant acquired pneumonia and deep airway infections.] Pneumologie 2005; 59: 612-664.
16. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1-iii55.
17. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72. (Pubitemid 46290553)
18. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. (Pubitemid 41829947)
19. Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008; 31: 349-355.
20. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005; 128: 2223-2229. (Pubitemid 41507563)
21. Hirakata Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with communityacquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 170-174. (Pubitemid 351680368)
22. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004; 32: 234-238.
23. Mauch H, Wagner J, Marklein G. Infektionen der tiefen Atemwege Teil I und Teil I. In: Mauch H, Lütticken R, Gatermann S, eds. Qualitä tsstandards in der Mikrobiologisch-Infektiologischen Diagnostik. Gustav-Fischer-Verlag, Jena, 1999; pp. 19-42.
24. Mauch H, Wagner J, Marklein G. Infektionen der tiefen Atemwege Teil I und Teil II. In: Mauch H, Lütticken R, Gatermann S, eds. Qualitä tsstandards in der Mikrobiologisch-Infektiologischen Diagnostik. Gustav-Fischer-Verlag, Jena, 1999; pp. 66-76.
25. RKI. Saisonabschlussbericht der Arbeitsgemeinschaft Influenza 2002/2003, 2003/2004, 2004/2005, 2005/2006. http://influenza.rki.de/Saisonbericht.aspx. Date last accessed: August 8, 2010.
26. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19: 571-582. (Pubitemid 44134311)
27. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186: 341-350. (Pubitemid 34816317)
28. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004; 172: 7603-7609. (Pubitemid 38747624)
29. Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006; 6: 303-312.
30. Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658-666. (Pubitemid 47444564)
31. Eurich DT, Marrie TJ, Johnstone J, et al. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178: 527-533.